KOC
RPRX icon

Koss-Olinger Consulting’s Royalty Pharma RPRX Stock Holding History

Koss-Olinger Consulting’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,142
Closed -$1.16M – 237
2026
Q1 		$1.16M Sell
24,142
-163
-0.7% -$7.14K 0.1% 77
2025
Q4 		$939K Sell
24,305
-7,063
-23% -$269K 0.07% 99
2025
Q3 		$1.13M Sell
31,368
-35
-0.1% -$1.27K 0.09% 115
2025
Q2 		$1.13M Sell
31,403
-353
-1% -$11.7K 0.09% 114
2025
Q1 		$989K Buy
31,756
+21,225
+202% +$673K 0.08% 120
2024
Q4 		$269K Buy
+10,531
New +$279K 0.02% 164

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Koss-Olinger Consulting's RPRX Position: Q2 2026 in Review

Koss-Olinger Consulting sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 24,142 shares — an estimated $1.16M sold.

Koss-Olinger Consulting first reported a position in RPRX in Q4 2024 and held it in 6 quarters. The position peaked at $1.16M in Q1 2026. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Koss-Olinger Consulting reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Koss-Olinger Consulting sold 24,142 Royalty Pharma shares in Q2 2026, an estimated $1.16M.
  • Koss-Olinger Consulting first reported a position in Royalty Pharma in Q4 2024 and held it in 6 quarters.
  • Koss-Olinger Consulting's Royalty Pharma position peaked at $1.16M in Q1 2026.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Koss-Olinger Consulting's 13F filing for Q2 2026, filed 10 Aug 2026.